Cholinesterase activities and biochemical determinations in patients with prostate cancer: Influence of Gleason score, treatment and bone metastasis

Biomedicine and Pharmacotherapy

Volumn 66, Issue 4, 2012, Pages 249-255

  Battisti, Vanessa ^a   Bagatini, Margarete D ^b   Maders, Liési D K ^a   Chiesa, Juarez ^a   Santos, Karen F ^a   Gonçalves, Jamile F ^c   Abdalla, Fátima H ^a   Battisti, Iara E ^b   Schetinger, Maria R C ^a   Morsch, Vera M ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^b UNIVERSIDADE FEDERAL DA FRONTEIRA SUL   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Acetylcholinesterase; Butyrylcholinesterase; Prostate cancer

Indexed keywords

ACETYLCHOLINESTERASE; ALBUMIN; CHOLINESTERASE; CYPROTERONE ACETATE; GOSERELIN; LACTATE DEHYDROGENASE;

AGED; ARTICLE; BONE METASTASIS; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CONTROLLED STUDY; ELECTROLYTE BALANCE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; GLEASON SCORE; HUMAN; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SMOKING;

ACETYLCHOLINESTERASE; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BUTYRYLCHOLINESTERASE; CASE-CONTROL STUDIES; HUMANS; MALE; NEOPLASM GRADING; PROSTATIC NEOPLASMS;

EID: 84862493511     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.11.005     Document Type: Article

References (53)

1. Routh M.D., Leibovich B.C. Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease. Mayo Clin Proc 2005, 80(7):899-907.
2. Parkin M.D., Bray F., Ferlay J., Pisani P. Global Cancer Statistics 2002. CA Cancer J Clin 2005, 55:74-108.
3. Gleason D.F Classification of prostatic carcinomas. Cancer Chemother Rep 1966, 50:125-128.
4. Gleason D.F. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992, 23:273-279.
5. Brawley O.W., Knopf K., Thompson I. The epidemiology of prostate cancer part II: the risk factors. Semin Urol Oncol 1998, 16:193-201.
6. Ahn J., Moslehi R., Weinstein S.J., Snyder K., Virtamo J., Albanes D. Family history of prostate cancer and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention (ATBC) study. Int J Cancer 2008, 123:1154-1159.
7. Suzuki T., Matsuo K., Wakai K., Hiraki A., Hirose K., Sato S., et al. Effect of familial history and smoking on common cancer risks in Japan. Cancer 2007, 109:2116-2123.
8. Dennis L.K., Hayes R.B. Alcohol and prostate cancer. Epidemiol Rev 2001, 23(1):110-114.
9. Levi F., La Vecchia C. Tobacco smoking and prostate cancer: time for an appraisal. Ann Oncol 2001, 12(6):733-738.
10. Parent M.E., Siemiatycki J. Occupation and prostate cancer. Epidemiol Rev 2001, 23(1):138-143.
11. Anderson J., Sternberg C.N., Kannan K., Jain S.K. Oxidative stress and apoptosis. Pathophysiology 2000, 7:153-163.
12. Anderson J. Treatment of prostate cancer-the role of primary hormonal therapy. EAU Update Series 2003, 1:32-39.
13. Hellerstedt B.A., Pienta K.J. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002, 52:154-179.
14. Darvesh S., Hopkins D.A., Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 2003, 4:131-138.
15. Stephenson J., Czepulkowski B., Hirst W., Mufti G.J. Deletion of the acetylcholinesterase locus at 7q22 associated with myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). Leuk Res 1996, 20:235-241.
16. Layer P.G., Willbold E. Novel functions of cholinesterases in development, physiology and disease. Prog Histochem Cytochem 1995, 29:1-94.
17. Montenegro M.F., Nieto-Cerón S., Ruiz-Espejo F., Cadena M.P., Rodriguez-Berrocal F.J., Vidal C.J. Cholinesterase activity and enzyme components in healthy and cancerous human colorectal sections. Chem Biol Interact 2005, 15:429-430.
18. Vidal C.J. Expression of cholinesterases in brain and non-brain tumours. Chem Biol Interact 2005, 15:227-232.
19. Zakut H., Ehrlich G., Ayalon A., Prody C.A., Malinger G., Seidman S., et al. Acetylcholinesterase and butyrylcholinesterase genes coamplify in primary ovarian carcinomas. J Clin Invest 1990, 86:900-908.
20. Bernardi C.C., Ribeiro E., Cavalli I.J., Maia E.A., Souza R. Amplification and deletion of the AChE and BChE cholinesterase genes in sporadic breast cancer. Cancer Genet Cytogenet 2010, 197:158-165.
21. Patocka J., Kuca K., Jun D. Acetylcholinesterase and butyrylcholinesterase-important enzymes of human body. Acta Med 2004, 47:215-228.
22. Paleari L., Grozio A., Cesario A., Russo P. The cholinergic system and cancer. Semin Cancer Biol 2008, 18:211-217.
23. Fossa S.D., Dearnaley D.P., Law M., Gad J., Newling D.W., Tveter K. Prognostic factors in hormone-resistant progressing cancer of the prostate. Ann Oncol 1992, 3:361-366.
24. Givens M.L., Crandall J. Renal complications in oncologic patients. Hematol Oncol Clin N Am 2010, 24:567-575.
25. Smaletz O., Scher H.I., Small E.J., Verbel D.A., McMillan A., Regan K., et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002, 20:3972-3982.
26. Sonpavde G., Pond G.R., Berry W.R., Wit R., Armstrong A.J., Eisenberger M.A., et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol 2010, in press. 10.1016/j.urolonc.2010.07.002.
27. Targher G. Elevated serum gamma-glutamyltransferase activity is associated with increased risk of mortality, incident type 2 diabetes, cardiovascular events, chronic kidney disease and cancer-a narrative review. Clin Chem Lab Med 2010, 48(2):147-157.
28. Lis C.G., Grutsch J.F., Vashi P.G., Lammersfeld C.A. Is serum albumin an independent predictor of survival in patients with breast cancer?. J Parenter Enteral Nutr 2003, 27:10-15.
29. Battisti V., Schetinger M.R., Maders L.D., Santos K.F., Bagatini M.D., Correa M.C., et al. Changes in acetylcholinesterase (AChE) activity in lymphocytes and whole blood in acute lymphoblastic leukemia patients. Clin Chim Acta 2009, 402:114-118.
30. Corrêa M.C., Maldonado P., Rosa C.S., Lunkes G., Lunkes D.S., Kaizer R.R., et al. Oxidative stress and erythrocyte acetylcholinesterase (AChE) in hypertensive and ischemic patients of both acute and chronic stages. Biomed Pharmacother 2008, 62:317-324.
31. Ellman G.L., Courtney D.K., Andres V., Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961, 7:88-95.
32. Worek F., Mast U., Kiderlen D., Diepold D., Eyer P. Improved determination of acetylcholinesterase activity in human whole blood. Chim Clin Acta 1999, 288:73-90.
33. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:218-254.
34. Sridhar G., Masho S.W., Adera T., Ramakrishnan V., Roberts J.D. Association between family history of cancers and risk of prostate cancer. J Men's Health 2010, 7:45-54.
35. Ditre J.W., Gonzalez B.D., Simmons V.N., Faul L.A., Brandon T.H., Jacobsen P.B. Associations between pain and current smoking status among cancer patients. Pain 2011, 152:60-65.
36. Rodgman A., Smith C.J., Perfetti T.A. The composition of cigarette smoke: a retrospective, with emphasis on polycyclic components. Human Exp Toxicol 2000, 19:573-595.
37. Liu S., Lee I.M., Linson P., Ajani U., Buring J.E., Hennekens C.H. A prospective study of physical activity and risk of prostate cancer in US physicians. Int J Epidemiol 2000, 29:29-35.
38. Jin Q.H., He H.Y., Shi Y.F., Lu H., Zhang X.J. Overexpression of acetylcholinesterase inhibited cell proliferation and promoted apoptosis in NRK cells. Acta Pharmacol Sin 2004, 25(8):1013-1021.
39. Zhang X.J., Yang L., Zhao Q., Caen J.P., He H.Y., Jin Q.H., et al. Induction of acetylcholinesterase expression during apoptosis in various cell types. Cell Death Differ 2002, 9(8):790-800.
40. Song P., Sekhon H.S., Jia Y., Keller J.A., Blusztajn J.K., Mark G.P., et al. Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. Cancer Res 2003, 63:214-221.
41. Ruiz-Espejo F., Cabezas-Herrera J., Illana J., Campoy F.J., Vidal C.J. Cholinesterase activity and acetylcholinesterase glycosylation are altered in human breast cancer. Breast Cancer Res Treat 2002, 72:11-22.
42. Ruiz-Espejo F., Cabezas-Herrera J., Illana J., Campoy F.J., Munoz-Delgado E., Vidal C.J. Breast cancer metastasis alters acetylcholinesterase activity and thecomposition of enzyme forms in axillary lymph nodes. Breast Cancer Res Treat 2003, 80:105-114.
43. Perry C., Sklan E.H., Birikh K., Shapira M., Trejo L., Eldor A., et al. Complex regulation of acetylcholinesterase gene expression in human brain tumors. Oncogene 2002, 21:8428-8441.
44. Motamed-Khorasani A., Jurisica I., Letarte M., Shaw P.A., Parkes R.K., Zhang X., et al. Differentially androgen modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression. Oncogene 2007, 26:198-214.
45. Nieto-Cerón S., Vargas-López H., Pérez-Albacete, Tovar-Zapata I., Martínez-Hernández P., Rodríguez-López J., et al. Analysis of cholinesterases in human prostate and sperm. Implications in cancer and fertility. Chem Biol Interact 2010, 187:432-435.
46. Layer P.G., Weikert T., Albert R. Cholinesterase regulate neurite growth of chick nerve cells in vitro by means of a non-enzymatic mechanism. Cell Tissue Res 1993, 273(2):219-226.
47. Robitzki A., Mack A., Hoppe U., Chatonnet A., Layer P.G. Butyrylcholinesterase antisense transfection increased apoptosis in differentiating retinal reagregattes of the chick embryo. J Neurochem 1998, 71(4):413-420.
48. Layer P.G., Sporns O. Spatiotemporal relation of embryonic cholinesterase with cell proliferation in chick brain and eye. Proc Natl Acad Sci U S A 1987, 84:284-288.
49. Layer P.G., Albert R., Rathjen F.G. Sequential activation of butyrylcholinesterase in rostral half somites and acetylcholinaesterase in motoneurones and myotomesmyotomes preceding growth of motor axons. Development 1988, 102:387-396.
50. Suh S., Ahn H. Lactate dehydrogenase as a prognostic factor for survival time of terminally ill cancer patients: a preliminary study. Eur J Cancer 2007, 43:1051-1059.
51. Hemelrijck M.V., Jassem W., Walldius G., Fentiman I.S., Hammar N., Lambe M., et al. Gamma-glutamyltransferase and risk of cancer in a cohort of 545,460 persons-the Swedish AMORIS study. Eur J Cancer 2011, 47(13):2033-2041.
52. Tandon P.K., Rizvi A.A. Hypocalcemia and parathyroid function in metastatic prostate cancer. Endocr Pract 2005, 11(4):254-258.
53. Shibata H. Cancer and electrolytes imbalance. Gan To Kagaku Ryoho 2010, 37(6):1006-1010.